Merck's #ESMO22 booth (Max Gelman/Endpoints News)

September 12, 2022 06:15 AM EDTUpdated 11:15 AM

#ESMO22: 'End of the beginning': As PD-(L)1s press on, how far can combo therapies take immuno-oncology?

Max Gelman

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Is there still hope for Summit's cancer drug buried in the data?

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

Regeneron makes $80M obesity deal with Hansoh

At a crossroads, biotechs are passing on reverse mergers in 2025

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...